Overview

To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM

Status:
Recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204
Phase:
Phase 3
Details
Lead Sponsor:
JW Pharmaceutical